Echocardiographic assessment of fabry cardiomyopathy: Early diagnosis and follow-up

Journal of the American Society of Echocardiography

Volumn 24, Issue 9, 2011, Pages 1033-1036

  Pieroni, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; NOTE; QUALITY OF LIFE; TISSUE DOPPLER IMAGING;

EID: 80052040080     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2011.07.012     Document Type: Editorial

References (31)

1. R.J. Desnick, Y.A. Ioannou, and C.M. Eng α-Galactosidase A deficiency Fabry disease C.R. Scriver, A.L. Beaudet, W.S. Sly, The metabolic and molecular bases of inherited disease 2001 McGraw-Hill New York 3733 3774
2. C. Kampmann, F. Baehner, C. Whybra, C. Martin, C.M. Wiethoff, and M. Ries Cardiac manifestations of Anderson-Fabry disease in heterozygous females J Am Coll Cardiol 40 2002 1668 1674 (Pubitemid 35253646)
3. M. Pieroni, C. Chimenti, F. De Cobelli, E. Morgante, A. Del Maschio, and C. Gaudio Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization J Am Coll Cardiol 47 2006 1663 1671 (Pubitemid 44313825)
4. B. Sachdev, T. Takenaka, H. Teraguchi, C. Tei, P. Lee, and W.J. McKenna Prevalence of Anderson-Fabry disease in male patients with late-onset hypertrophic cardiomyopathy Circulation 105 2002 1407 1411 (Pubitemid 34263268)
5. L. Monserrat, J.R. Gimeno-Blanes, F. Marín, M. Hermida-Prieto, A. García-Honrubia, and I. Pérez Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 50 2007 2399 2403 (Pubitemid 50011583)
6. S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, and M. Tahara An atypical variant of Fabry's disease in men with left ventricular hypertrophy N Engl J Med 333 1995 288 293
7. M. Elleder, V. Bradova, F. Smid, M. Budesinsky, K. Harzer, and B. Kustermann-Kuhn Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy Virchows Arch A Pathol Anat Histopathol 417 1990 449 455 (Pubitemid 20345820)
8. A. Linhart, T. Palecek, J. Bultas, J.J. Ferguson, J. Hrudova, and D. Karetova New insights in cardiac structural changes in patients with Fabry's disease Am Heart J 139 2000 1101 1108 (Pubitemid 30390343)
9. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, and S. Waldek Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease N Engl J Med 345 2001 9 16 (Pubitemid 32634266)
10. R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, and T. Weibel Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2001 2743 2749 (Pubitemid 32525371)
11. F. Weidemann, M. Niemann, F. Breunig, S. Herrmann, M. Beer, and S. Störk Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment Circulation 119 2009 524 529
12. M. Pieroni, C. Chimenti, R. Ricci, P. Sale, M.A. Russo, and A. Frustaci Early detection of Fabry cardiomyopathy by tissue Doppler imaging Circulation 107 2003 1978 1984 (Pubitemid 36506070)
13. F. Weidemann, F. Breunig, M. Beer, J. Sandstede, S. Störk, and W. Voelker The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease Eur Heart J 26 2005 1221 1227 (Pubitemid 40863129)
14. C. Chimenti, N. Hamdani, N.M. Boontje, F. DeCobelli, A. Esposito, and J.G. Bronzwaer Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease Am J Pathol 172 2008 1482 1490 (Pubitemid 351793342)
15. M. Niemann, S. Herrmann, K. Hu, F. Breunig, J. Strotmann, and M. Beer Differences in Fabry cardiomyopathy between female and male patients consequences for diagnostic assessment JACC Cardiovasc Imaging 4 2011 592 601
16. F. Weidemann, J.M. Strotmann, F. Breunig, M. Niemann, R. Maag, and R. Baron Misleading terms in Anderson-Fabry disease Eur J Clin Invest 38 2008 191 196 (Pubitemid 351197096)
17. M. Niemann, F. Breunig, M. Beer, K. Hu, D. Liu, and A. Emmert Tei index in Fabry disease J Am Soc Echocardiogr 24 2011 1026 1032
18. C. Tei, L.H. Ling, D.O. Hodge, K.R. Bailey, J.K. Oh, and R.J. Rodeheffer New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy J Cardiol 26 1995 357 366 (Pubitemid 26011184)
19. K.J. Harjai, L. Scott, K. Vivekananthan, E. Nunez, and R. Edupuganti The Tei index: a new prognostic index for patients with symptomatic heart failure J Am Soc Echocardiogr 15 2002 864 868
20. W.H. Kim, Y. Otsuji, T. Yuasa, S. Minagoe, J.B. Seward, and C. Tei Evaluation of right ventricular dysfunction in patients with cardiac amyloidosis using Tei index J Am Soc Echocardiogr 17 2004 45 49 (Pubitemid 38064114)
21. K. Vivekananthan, T. Kalapura, M. Mehra, C. Lavie, R. Milani, and R. Scott Usefulness of the combined index of systolic and diastolic myocardial performance to identify cardiac allograft rejection Am J Cardiol 90 2002 517 520 (Pubitemid 35246042)
22. M. Belham, A. Kruger, S. Mepham, G. Faganello, and C. Pritchard Monitoring left ventricular function in adults receiving anthracycline- containing chemotherapy Eur J Heart Fail 9 2007 409 414 (Pubitemid 46441967)
23. T. Watt, A.P. Burlina, C. Cazzorla, D. Schönfeld, M. Banikazemi, and R.J. Hopkin Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry Genet Med 12 2010 703 712
24. L. Spinelli, A. Pisani, M. Sabbatini, M. Petretta, M.V. Andreucci, and D. Procaccini Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease Clin Genet 66 2004 158 165 (Pubitemid 39117524)
25. F. Weidemann, F. Breunig, M. Beer, J. Sandstede, O. Turschner, and W. Voelker Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study Circulation 108 2003 1299 1301 (Pubitemid 37174405)
26. J.W. Koskenvuo, J.J. Hartiala, P. Nuutila, R. Kalliokoski, J.S. Viikari, and E. Engblom Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters J Inherit Metab Dis 31 2008 432 441
27. M. Kovacevic-Preradovic Zuber, C.H. Attenhofer Jost, U. Widmer, B. Seifert, and G. Schulthess Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy Eur J Echocardiogr 9 2008 729 735
28. M. Beer, F. Weidemann, F. Breunig, F. Breunig, A. Knoll, and S. Koeppe Impact of enzyme replace therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy Am J Cardiol 97 2006 1515 1518
29. P.M. Elliott, H. Kindler, J.S. Shah, B. Sachdev, O.E. Rimoldi, and R. Thaman Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A Heart 92 2006 357 360
30. A. Mehta, J.T. Clarke, R. Giugliani, P. Elliott, A. Linhart, M. Beck FOS Investigators Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey J Med Genet 46 2009 548 552
31. B.L. Thurberg, J.T. Fallon, R. Mitchell, T. Aretz, R.E. Gordon, and M.W. O'Callaghan Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy Circulation 119 2009 2561 2567